Yıl: 2016 Cilt: 22 Sayı: 1 Sayfa Aralığı: 18 - 22 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Hepatit C Enfeksiyonunun Tanısında Hepatit C Virüsü Kor Antijen Testinin Etkinliği

Öz:
Amaç: Hepatit C virüsü (HCV) kor antijen testinin tanı değerinin antiHCV testi pozitif veya negatif olan hastalarda HCV ribonükleik asit (RNA) ile kıyaslanarak araştırılmasıdır.Gereç ve Yöntemler: Necmettin Erbakan Üniversitesi Üniversitesi Meram Tıp Fakültesi'ne Aralık 2010- Şubat 2012 tarihleri arasında başvuran ve çeşitli nedenlerle HCV RNA testi çalışılan 189 hastadan elde edilen serum örnekleri bu çalışmaya dahil edildi. İki mL serum örneği uygun koşullar altında saklandı ve anti HCV, HCV kor antijen ve strip immünblot testi [Ticari INNO LIA(TM) HCV Score testi (Innogenetics NV in Ghent, Belçika)] testleri çalışıldı. HCV RNA pozitif olan örneklere genotipleme yapıldıBulgular: Çalışmamızda HCV kor antijen testinin sensitivite, spesifite; negatif prediktif değer ve pozitif prediktif değerleri sırayla %96,2, %100, %97,3 ve %100 olarak tespit edildi. Genotipleme yapılan 65 örneğin 59'u genotip 1b, 2'si genotip 1a/1b, 1'i genotip 3a, 1'i genotip 4, 1'i genotip 2a/2c ve 1'i genotip 1a olarak tespit edildi.Sonuç: HCV kor antijen testi sensitivitesi ve spesifitesi yüksek, kolay uygulanabilir, güvenilir bir testtir. Bu test HCV enfeksiyonunun tanısında anti-HCV test sonuçlarının konfirmasyon ve tamamlayıcı testi olarak kullanılabilir.
Anahtar Kelime:

Konular: Genel ve Dahili Tıp Mikrobiyoloji Hematoloji Biyoteknoloji ve Uygulamalı Mikrobiyoloji Viroloji Enfeksiyon Hastalıkları Tıbbi Laboratuar Teknolojisi

The Efficiency of Hepatitis C Virus Core Antigen Test in the Diagnosis of Hepatitis C Infection

Öz:
Objective: It was aimed to investigate diagnostic value of hepatitis C virus (HCV) core antigen test in patients with positive or negative anti-HCV assay by comparing with HCV ribonucleic acid (RNA) assay.Materials and Methods: Serum samples obtained from 189 patients who were admitted to Necmettin Erbakan University Meram Faculty of Medicine between December 2010 and February 2012, and HCV RNA assay were carried out for various reasons. Two mL of samples were stored under suitable conditions and antiHCV, HCV core antigen and strip immunoblot assay [Commercial INNO LIA(TM) HCV Score (Innogenetics NV in Ghent, Belgium)] were performed. Genotyping was performed in the amplicons of the samples with positive HCV RNA test.Results: The diagnostic sensitivity specificity, negative predictive value and positive predictive value of HCV core antigen test were 96.2%, 100%, 97.3%, and 100%, respectively. Sixty-five serum samples were genotyped and their distribution were detected: Fiftynine samples were genotype 1b, 2-genotype 1a/1b, 1-genotype 3a, 1-genotype 4, 1-genotype 2a/2c, and 1 was genotype 1a.Conclusion: It was concluded that HCV core antigen assay is highly specific, sensitive, reliable, reproducible, and easy to perform. It may be applied as a supplemental and confirmatory test in anti-HCV assays in the diagnosis of HCV.
Anahtar Kelime:

Konular: Genel ve Dahili Tıp Mikrobiyoloji Hematoloji Biyoteknoloji ve Uygulamalı Mikrobiyoloji Viroloji Enfeksiyon Hastalıkları Tıbbi Laboratuar Teknolojisi
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Suzuki T. Morphogenesis of infectious hepatitis C virus particles. Front Microbiol. 2012;3:38.
  • 2. Scott JD, Gretch DR. Hepatitis C and G viruses. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (eds.), Manual of Clinical Microbiology. 9th ed. Ankara: Atlas Publishing; 2007; p. 1437-1452.
  • 3. Alavian SM, Aalaei-Andabili SH. Lack of knowledge about hepatitis C infection rates among patients with inherited coagulation disorders in countries under the eastern mediterranean region office of WHO (EMRO): A Meta-Analysis. Hepat Mon. 2012;12:244-252.
  • 4. Paraboni ML, Sbeghen MD, Wolff FH, Moreira LB. Risk factors for infection with different hepatitis C virus genotypes in southern Brazil. Scientific World Journal. 2012;2012:946954.
  • 5. Pawlotsky JM, Prescott L, Simmonds P, Pellet C, Laurent-Puig P, Labonne C, Darthuy F, Remire J, Duval J, Buffet C,Etienne JP, Dhumeaux D, Dussaix E. Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. J Clin Microbiol. 1997;35:1734-1739.
  • 6. Çelik C, Bakıcı MZ, Kaygusuz R, Ertürk R. The searching of HCV genotyping distributions in the region of Sivas. Viral Hepatitis Journal. 2010;16:106-110.
  • 7. Gretch DR. Diagnostic tests for hepatitis C. Hepatology. 1997;26:43-47.
  • 8. Dufour DR, Talastas M, Fernandez MD, Harris B, Strader DB, Seeff LB. Low-positive anti-hepatitis C virus enzyme immunoassay results: an important predictor of low likelihood of hepatitis C infection. Clin Chem. 2003;49:479-486.
  • 9. Kesli R, Ozdemir M, Kurtoglu MG, Baykan M, Baysal B. Evaluation and comparison of three different anti-hepatitis C virus antibody tests based on chemiluminescence and enzyme-linked immunosorbent assay methods used in the diagnosis of hepatitis C infections in Turkey. J Int Med Res. 2009;37:1420-1429.
  • 10. Daniel HD, Vivekanandan P, Raghuraman S, Sridharan G, Chandy GM, Abraham P. Significance of the hepatitis C virus (HCV) core antigen as an alternative plasma marker of active HCV infection. Indian J Med Microbiol. 2007;25:37-42.
  • 11. Seme K, Poljak M, Babic DZ, Mocilnik T, Vince A. The role of core antigen detection in management of hepatitis C: a critical review. J Clin Virol. 2005;32:92-101.
  • 12. Hosseini-Moghaddam SM, Iran-Pour E, Rotstein C, Husain S, Lilly L, Renner E, Mazzulli T. Hepatitis C core Ag and its clinical applicability: potential advantages and disadvantages for diagnosis and follow-up? Rev Med Virol. 2012;22:156-165.
  • 13. Morota K, Fujinami R, Kinukawa H, Machida T, Ohno K, Saegusa H, Takeda K. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J Virol Methods. 2009;157:8-14.
  • 14. Acar A, Kemahli S, Altunay H, Kosan E, Oncul O, Gorenek L, Cavuslu S. HBV, HCV and HIV seroprevalence among blood donors in Istanbul, Turkey: how effective are the changes in the national blood transfusion policies? Braz J Infect Dis. 2010;14:41-46.
  • 15. Tbakur V, Guptan RC, Arankale V, Sarin SK. Low specificity of the third generation ELISA for HCV detection in voluntary blood donors in India. EJIFCC. 2003;14.
  • 16. Alter MJ, Kuhnert WL, Finelli L; Centersfor Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centersfor Disease Control and Prevention. MMWR Recomm Rep. 2003;7;52:1-13.
  • 17. Kesli R. An overview of the laboratory assay systems and reactives used in the diagnosis of hepatitis C virus (HCV) infections.In Abuelzein E ed. Trends in Immunolabelled and Related Techniques.In Tech Publishing House, Rijeka, Croatio; 2012:339-350.
  • 18. Mederacke I, Wedemeyer H, Ciesek S, Steinmann E, Raupach R, Wursthorn K, Manns MP, Tillmann HL. Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J Clin Virol. 2009;46:210-215.
  • 19. Chamie G, Bonacini M, Bangsberg DR, Stapleton JT, Hall C, Overton ET, Scherzer R, Tien PC. Factors associated with seronegative chronic hepatitis C virus infection in HIV infection. Clin Infect Dis. 2007;44:577-583.
  • 20. Vermehren J, Susser S, Berger A, Perner D, Peiffer KH, Allwinn R, Zeuzem S, Sarrazin C. Clinical utility of the Architect HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection. J Clin Virol. 2012;55:17-22
  • 21. Bouvier-Alias M, Patel K, Dahari H, Beaucourt S, Larderie P, Blatt L, Hezode C, Picchio G, Dhumeaux D, Neumann AU, McHutchison JG, Pawlotsky JM. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology. 2002;36:211-218.
  • 22. Saito R, Yokota H, Takahashi E, Mashige F, Yoneyama A, Nakahara K, Okamura N. Performance of an automated system for quantitation of hepatitis C virus core antigen. J Virol Methods. 2003;112: 93-97.
  • 23. Miedouge M, Saune K, Kamar N, Rieu M, Rostaing L, Izopet J. Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol. 2010;48:18- 21.
  • 24. Chevaliez S. Virological tools to diagnose and monitor hepatitis C virus infection. Clin Microbiol Infect. 2011;17:116-121.
  • 25. Kesli R, Polat H, Terzi Y, Kurtoglu MG, Uyar Y. Comparison of a newly developed automated and quantitative hepatitis C virus (HCV) core antigen test with the HCV RNA assay for clinical usefulness in confirming anti-HCV results. J Clin Microbiol. 2011;49:4089-4093.
  • 26. Chevaliez S, Pawlotsky JM. Hepatitis C virüs serologic and virologic tests and clinical diagnosis of HCV-related liver disease. Int J Med Sci. 2006;3:35-40.
  • 27. Daniel HD, Vivekanandan P, Raghuraman S, Sridharan G, Chandy GM, Abraham P. Significance of the hepatitis C virus (HCV) core antigen as an alternative plasma marker of active HCV infection. Indian J Med Microbiol. 2007;25:37-42.
  • 28. Yuksel P, Caliskan R, Ergin S, Aslan M, Celik DG, Saribas S, Ziver T, Yalciner A, Kocazeybek B. New approaches to in vitro diagnosis of hepatitis C infection a reason for post transfusion hepatitis: Diagnostic value of determination of hepatitis C virus core antigen. Transfus Apher Sci. 2011;45:247-250.
  • 29. Ergünay K, Sener B, Alp A, Karakaya J, Hasçelik G. Utility of a commercial quantitative hepatitis C virus core antigen assay in a diagnostic laboratory setting. Diagn Microbiol Infect Dis. 2011;70:486-491.
  • 30. Arıdoğan BC, Aynalı A, Kaya S, Onal S, Cetin ES. Comparison of HCV core antigen and anti-HCV with HCV RNA results. Afr Health Sci 2014;14:816-819
APA Demircili M, OZDEMIR M, Feyzioğlu B, BAYSAL B (2016). Hepatit C Enfeksiyonunun Tanısında Hepatit C Virüsü Kor Antijen Testinin Etkinliği. , 18 - 22.
Chicago Demircili Mehmet Emin,OZDEMIR MEHMET,Feyzioğlu Bahadır,BAYSAL Bülent Hepatit C Enfeksiyonunun Tanısında Hepatit C Virüsü Kor Antijen Testinin Etkinliği. (2016): 18 - 22.
MLA Demircili Mehmet Emin,OZDEMIR MEHMET,Feyzioğlu Bahadır,BAYSAL Bülent Hepatit C Enfeksiyonunun Tanısında Hepatit C Virüsü Kor Antijen Testinin Etkinliği. , 2016, ss.18 - 22.
AMA Demircili M,OZDEMIR M,Feyzioğlu B,BAYSAL B Hepatit C Enfeksiyonunun Tanısında Hepatit C Virüsü Kor Antijen Testinin Etkinliği. . 2016; 18 - 22.
Vancouver Demircili M,OZDEMIR M,Feyzioğlu B,BAYSAL B Hepatit C Enfeksiyonunun Tanısında Hepatit C Virüsü Kor Antijen Testinin Etkinliği. . 2016; 18 - 22.
IEEE Demircili M,OZDEMIR M,Feyzioğlu B,BAYSAL B "Hepatit C Enfeksiyonunun Tanısında Hepatit C Virüsü Kor Antijen Testinin Etkinliği." , ss.18 - 22, 2016.
ISNAD Demircili, Mehmet Emin vd. "Hepatit C Enfeksiyonunun Tanısında Hepatit C Virüsü Kor Antijen Testinin Etkinliği". (2016), 18-22.
APA Demircili M, OZDEMIR M, Feyzioğlu B, BAYSAL B (2016). Hepatit C Enfeksiyonunun Tanısında Hepatit C Virüsü Kor Antijen Testinin Etkinliği. Viral Hepatitis Journal, 22(1), 18 - 22.
Chicago Demircili Mehmet Emin,OZDEMIR MEHMET,Feyzioğlu Bahadır,BAYSAL Bülent Hepatit C Enfeksiyonunun Tanısında Hepatit C Virüsü Kor Antijen Testinin Etkinliği. Viral Hepatitis Journal 22, no.1 (2016): 18 - 22.
MLA Demircili Mehmet Emin,OZDEMIR MEHMET,Feyzioğlu Bahadır,BAYSAL Bülent Hepatit C Enfeksiyonunun Tanısında Hepatit C Virüsü Kor Antijen Testinin Etkinliği. Viral Hepatitis Journal, vol.22, no.1, 2016, ss.18 - 22.
AMA Demircili M,OZDEMIR M,Feyzioğlu B,BAYSAL B Hepatit C Enfeksiyonunun Tanısında Hepatit C Virüsü Kor Antijen Testinin Etkinliği. Viral Hepatitis Journal. 2016; 22(1): 18 - 22.
Vancouver Demircili M,OZDEMIR M,Feyzioğlu B,BAYSAL B Hepatit C Enfeksiyonunun Tanısında Hepatit C Virüsü Kor Antijen Testinin Etkinliği. Viral Hepatitis Journal. 2016; 22(1): 18 - 22.
IEEE Demircili M,OZDEMIR M,Feyzioğlu B,BAYSAL B "Hepatit C Enfeksiyonunun Tanısında Hepatit C Virüsü Kor Antijen Testinin Etkinliği." Viral Hepatitis Journal, 22, ss.18 - 22, 2016.
ISNAD Demircili, Mehmet Emin vd. "Hepatit C Enfeksiyonunun Tanısında Hepatit C Virüsü Kor Antijen Testinin Etkinliği". Viral Hepatitis Journal 22/1 (2016), 18-22.